A Guideline Development Group (GDG) meeting at the end of the month aims to establish new guidelines for lenacapavir, a twice ...

Morgan Stanley has upgraded Gilead Sciences (NASDAQ:GILD) to overweight from equal weight, citing the company's HIV drug ...

It is the first time that a PrEP trial has been shown to prevent any HIV infections from slipping through the net, according to Gilead, and showed a subcutaneous injection with lenacapavir every ...

A new drug is hugely effective at protecting people from HIV infection and needs to be injected only twice a year.

Science magazine has chosen twice-yearly lenacapavir PrEP as its 2024 Breakthrough of the Year, recognizing it as a game-changer in the fight to end the global HIV epidemic. Looking ahead, once-yearly ...

In a major step forward in the fight against HIV/AIDS, the US Food and Drug Administration (FDA) has approved Lenacapavir, an ...

A Gilead representative received a standing ovation at AIDS24, held in July in Munich, Germany, after unveiling data from the PURPOSE 1 trial (NCT04994509) of lenacapavir for HIV PReP. In a Phase ...

The study found that twice-yearly lenacapavir for pre-exposure prophylaxis (PrEP) was highly efficacious at reducing HIV infections, reducing them by 96% compared to background HIV incidence.

Sponsor MessageWeld points out that in both the PURPOSE 1 and PURPOSE 2 trials, it was notable that the participants randomized to receive daily oral PrEP instead of lenacapavir, showed low ...